

PSYCHIATRIC SOCIETY OF VIRGINIA
2023 PSV Spring Meeting

March 17 - 18, 2023

Richmond, VA

FRIDAY, MARCH 17, 2023

3:00 PM – 6:30 PM **Registration | Check In**

5:30 PM – 7:00 PM **Reception with Area Legislators and Exhibits**

SATURDAY, MARCH 18, 2023

7:45 AM – 3:00 PM **Registration**

7:45 AM – 8:45 AM **Committee Breakfast Meetings/Visit Exhibits open to all attendees**

8:45 AM – 9:00 AM **Welcome | Overview | Introductions**

9:00 AM – 9:45 AM **Transcranial Magnetic Stimulation: State of the Art & Future Opportunities**

Ananda K. Pandurangi, MD, MBBS, DLFAPA

Objectives:

1. Examine how TMS works.
2. Compare available devices and their strengths and limitations.
3. Integrate this therapy for the benefit of the patient.
4. Assess potential future developments in the field of TMS and Therapeutic Neuromodulation.

9:45 AM – 10:30 AM **APA Update: The Changing World of Psychiatry - APA and DB's Vision**

Saul Levin, MD, MPA, FRCP-E, FRCP-Psych

Objectives:

1. Examine Legislation
2. Interpret Rules and Regulations
3. Analyze Scope of Practice

10:30 AM – 11:00 AM **Break | Visit Exhibits**

11:00 AM – 11:45 AM **Precision Treatment of Psychiatric and Addictive Disorders with Machine Learning Models and Pharmacogenetics**

Albert Arias, MD

Objectives:

1. Evaluate and review recent research applying machine learning and pharmacogenetics to predicting treatment response to pharmacotherapy in depression and alcohol use disorder.

2. Recommend new approaches to treatment matching and contemplate their utility in practice.

11:45 AM – 1:00 PM

Lunch | Business Meeting | Visit Exhibits

1:00 PM – 1:45 PM

Debate: Psychedelic-Assisted Therapies in Serious Illness Care: Opportunities and Challenges

Alden Doerner Rinaldi, MD; Roxanne (Roxy) Sholevar, MD

Objectives:

1. Assess the landscape of psychological and existential/spiritual care in patients with serious illness.

2. Evaluate historical and modern research studies on psychedelic-assisted therapies in patients with serious illness.

3. Examine unique opportunities psychedelic-assisted therapies offer for healing and growth in patients with serious illness.

4. Interpret unique risks and dangers of psychedelic-assisted therapies in this vulnerable population.

1:45 PM – 2:30 PM

Precision Psychiatric Care: A Focus on Pharmacogenetics

David Oslin, MD

Objectives:

1. Evaluate the clinical utility of pharmacogenetics in psychiatric practice.

2. Examine the limitations of pharmacogenetic testing.

2:30 PM – 3:15 PM

Ketamine/Glutamatergic Treatments

Mark Niciu, MD

3:15 PM – 3:45 PM

Panel Discussion: Emerging Therapies - Frontiers in Psychiatry

Albert Arias, MD ; Alden Doerner Rinaldi, MD; Saul Levin, MD, MPA, FRCP-E, FRCP-Psych; Mark Niciu, MD; David Oslin, MD; Ananda K. Pandurangi, MD, MBBS, DLFAPA; Roxanne (Roxy) Sholevar, MD

3:45 PM

Closing Remarks